Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice

Ciltacabtagene autoleucel (cilta-cel) is a chimeric antigen receptor T-cell therapy studied in patients with multiple myeloma exposed to three classes of treatment in the single-arm CARTITUDE-1 study. To assess the effectiveness of cilta-cel compared to real-world clinical practice (RWCP), we perfor...

Descripción completa

Detalles Bibliográficos
Autores principales: Mateos, Maria-Victoria, Weisel, Katja, Martin, Thomas, Berdeja, Jesús G., Jakubowiak, Andrzej, Stewart, A. Keith, Jagannath, Sundar, Lin, Yi, Diels, Joris, Ghilotti, Francesca, Thilakarathne, Pushpike, Perualila, Nolen J., Cabrieto, Jedelyn, Haefliger, Benjamin, Erler-Yates, Nichola, Hague, Clare, Jackson, Carolyn C., Schecter, Jordan M., Strulev, Vadim, Nesheiwat, Tonia, Pacaud, Lida, Einsele, Hermann, Moreau, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2022
Materias:
Article - Cell Therapy & Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10388260/
https://www.ncbi.nlm.nih.gov/pubmed/36546453
http://dx.doi.org/10.3324/haematol.2022.280482

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10388260/
https://www.ncbi.nlm.nih.gov/pubmed/36546453
http://dx.doi.org/10.3324/haematol.2022.280482

Ejemplares similares